<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324831</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000466677</org_study_id>
    <secondary_id>FAV-ID-11</secondary_id>
    <secondary_id>FAV-WIRB-20051774</secondary_id>
    <nct_id>NCT00324831</nct_id>
  </id_info>
  <brief_title>GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>Phase III, Double-Blind, Randomized, Placebo-Controlled Trial of FavID® (Id/KLH) and GM-CSF Following CHOP/Rituximab as First-Line Therapy in Subjects With High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Favrille</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine,&#xD;
      and prednisone, work in different ways to stop the growth of cancer cells, either by killing&#xD;
      the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can&#xD;
      block cancer growth in different ways. Some block the ability of cancer cells to grow and&#xD;
      spread. Others find cancer cells and help kill them or carry cancer-killing substances to&#xD;
      them. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells&#xD;
      found in bone marrow or peripheral blood and may help the immune system recover from the side&#xD;
      effects of chemotherapy. Vaccines made from a person's cancer cells may help the body build&#xD;
      an effective immune response to kill cancer cells. It is not yet known whether giving GM-CSF&#xD;
      together with vaccine therapy is more effective than giving GM-CSF together with a placebo&#xD;
      when given after combination chemotherapy and rituximab in treating diffuse large B-cell&#xD;
      lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying GM-CSF and vaccine therapy to see how&#xD;
      well they work compared to GM-CSF and placebo when given after combination chemotherapy and&#xD;
      rituximab as first-line therapy in treating patients with stage II, stage III, or stage IV&#xD;
      diffuse large B-cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the 3-year disease-free survival of patients with high-intermediate- or&#xD;
           high-risk bulky stage II or stage III or IV diffuse large B-cell lymphoma treated with&#xD;
           sargramostim (GM-CSF) with or without autologous immunoglobulin idiotype-KLH conjugate&#xD;
           vaccine (FavId®) after combination chemotherapy comprising cyclophosphamide,&#xD;
           doxorubicin, vincristine, prednisone, and rituximab (CHOP-R).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the 2-year disease-free survival, duration of response, time to progression,&#xD;
           overall survival, and safety in patients treated with these regimens.&#xD;
&#xD;
        -  Estimate the rate of immune reactivity to FavId®.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are&#xD;
      stratified according to risk score (3 [high-intermediate] vs 4 or 5 [high]).&#xD;
&#xD;
        -  Chemotherapy: Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV,&#xD;
           vincristine IV, and rituximab IV on day 1 and oral prednisone on days 1-5. Treatment&#xD;
           repeats every 21 days for up to 8 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Sargramostim (GM-CSF) with or without autologous immunoglobulin idiotype-KLH conjugate&#xD;
           vaccine (FavId®): Patients achieving complete remission (CR) or unconfirmed CR after&#xD;
           chemotherapy and who have FavId® available are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive FavId® vaccine subcutaneously (SC) on day 1. Patients also&#xD;
                receive sargramostim (GM-CSF) SC on days 1-4.&#xD;
&#xD;
             -  Arm II: Patients receive placebo SC on day 1 and GM-CSF SC as in arm I. In both&#xD;
                arms, treatment repeats once a month for 6 months and then once every 2 months for&#xD;
                24 months (18 total vaccinations) in the absence of disease progression or&#xD;
                unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 480 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival as measured by the Kaplan-Meier method at 3 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival as measured by the Kaplan-Meier method at 2 years</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (complete or partial response)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall disease-free survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologous immunoglobulin idiotype-KLH conjugate vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intervention/procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colony-stimulating factor therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytokine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>monoclonal antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>non-specific immune-modulator therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tumor cell derivative vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vaccine therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diffuse large B-cell lymphoma&#xD;
&#xD;
               -  Bulky stage II or stage III or IV disease&#xD;
&#xD;
               -  Treatment naïve&#xD;
&#xD;
               -  International Prognostic Index score of 3 (high-intermediate) or 4/5 (high)&#xD;
&#xD;
          -  Lymphoma accessible for sampling or existing biopsy material judged suitable for&#xD;
             preparation of autologous immunoglobulin idiotype-KLH conjugate vaccine (FavId®)&#xD;
&#xD;
          -  No history of CNS lymphoma or meningeal lymphomatosis&#xD;
&#xD;
          -  No history of indolent lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mm^3&#xD;
&#xD;
          -  ALT and AST &lt; 2 times upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No history of unresolved hepatitis B viral infection&#xD;
&#xD;
          -  No history of a treated prior malignancy unless in remission ≥ 2 years, except for&#xD;
             treated nonmelanoma carcinomas of the skin or in situ cervical carcinomas or prostatic&#xD;
             carcinomas&#xD;
&#xD;
          -  No contraindication to doxorubicin hydrochloride (e.g., abnormal contractility on ECG)&#xD;
&#xD;
          -  No contraindication to vincristine (e.g., peripheral neuropathy)&#xD;
&#xD;
          -  No know HIV positivity&#xD;
&#xD;
          -  No serious nonmalignant disease, including any of the following:&#xD;
&#xD;
               -  Psychiatric disorders&#xD;
&#xD;
               -  Compromised pulmonary function&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Active bacterial, viral, or fungal infections&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior keyhole limpet hemocyanin&#xD;
&#xD;
          -  No planned radiotherapy during or after study therapy&#xD;
&#xD;
          -  No concurrent systemic immunosuppressive therapy (e.g., steroids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F. Bender, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Favrille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tower Cancer Research Foundation</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>May 10, 2006</study_first_submitted>
  <study_first_submitted_qc>May 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Immunoglobulin Idiotypes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

